Advanced Glycosylation End Product (AGE) antibody

Antigen: Advanced Glycosylation End Product (AGE)

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human

Application: Immunohistochemistry (Frozen Sections) (IHC (fro)), Enzyme Immunoassay (EIA)

Catalog no.: ABIN113995

Additional Information

Characteristics: Synonyms: Advanced Glycation End Products

Alternative name: AGE

Immunogen: Advanced Glycation End Products /BSA/HSA

Description: Long-term incubation of proteins with glucose leads, through Schiff's base and Amadorirearrangement products, to the formation of advanced glycation end products (AGE) whichare characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence ofAGE in (1) human lens, (2) renal proximal tubules in patients with diabetic nephropathyand chronic renal failure, (3) atherosclerotic lesions of arterial walls, (4)beta2-microglobulin of carpal tunnel amyloid fibril deposits in patients withhemodialysis-related amyloidosis and (5) brain tissues of patients with Alzheimersdisease. These results suggested the potential role of AGE in normal aging andage-enhanced disease processes.

Specificity: Recognizes Advanced Glycation End Products (AGE), cross-reactivity with BSA and HSA <1%. Species: Human. Others not tested.

Application Details

Application Notes: This antibody is suitable for the detection of different AGE products in tissues, tissueextracts and body fluids. ELISA (~1 µg/ml). Immunohistochemistry (2-10 µg/ml). Incubation time: 60 min at RT or 18 h at 4°C. Positive Control: Human lens, arteriosclerotic plaques. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Concentration: 1.0 mg/ml

Buffer: 0.01M PBS, pH 7.15 containing 0.85% Sodium Chloride. 0.5% BSA asstabilizer and 0.09% Sodium Azide as preservative.

Storage: Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.

Research Area: Cancer, Atherosclerosis, Metabolism

Restrictions: For Research Use only

Publications

Publications: Matsumoto, Iida, Motoya et al.: "Therapeutic Efficacy of Infliximab on Patients with Short Duration of Crohn's Disease: A Japanese Multicenter Survey." in: Diseases of the colon and rectum, 2008 (PubMed).